{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:32:53Z","timestamp":1793968373296,"version":"4.8.0"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","funder":[{"DOI":"10.13039\/sppvl2rk4okz","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82400130"],"award-info":[{"award-number":["82400130"]}],"id":[{"id":"10.13039\/sppvl2rk4okz","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/spggphjsyvtv","name":"The Youth Independent Innovation Science Fund Project of the PLA General Hospital","doi-asserted-by":"publisher","award":["22QNFC134"],"award-info":[{"award-number":["22QNFC134"]}],"id":[{"id":"10.13039\/spggphjsyvtv","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/sp7ejukhon0w","name":"The National Natural Science Foundation Pre-Research Project of the Second Medical Center of the PLA General Hospital","doi-asserted-by":"publisher","award":["YYM2412"],"award-info":[{"award-number":["YYM2412"]}],"id":[{"id":"10.13039\/sp7ejukhon0w","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>\n                      The emergence of a linezolid minimum inhibitory concentration creep (2\u20134 mg\/L) necessitates higher trough concentrations (C\n                      <jats:sub>min<\/jats:sub>\n                      ), which may increase the risk of hematological side effects. Evaluating the effects of different linezolid C\n                      <jats:sub>min<\/jats:sub>\n                      levels on hematological indices and determining a new target C\n                      <jats:sub>min<\/jats:sub>\n                      range are essential.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Elderly patients receiving linezolid at 4 tertiary hospitals between May 2021 and March 2024 were grouped according to their C\n                      <jats:sub>min<\/jats:sub>\n                      levels. Linezolid C\n                      <jats:sub>min<\/jats:sub>\n                      and hematological indices were monitored dynamically.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 320 patients were enrolled, and 128 patients were included in the analysis of hematological side effects following propensity score matching between C\n                      <jats:sub>min<\/jats:sub>\n                      &gt;16 mg\/L and C\n                      <jats:sub>min<\/jats:sub>\n                      \u226416 mg\/L. The incidence of thrombocytopenia and the reduction in platelet count were significantly greater in patients with C\n                      <jats:sub>min<\/jats:sub>\n                      &gt;16 mg\/L compared with those with C\n                      <jats:sub>min<\/jats:sub>\n                      \u226416 mg\/L. However, no significant differences were observed in the incidence of anemia or changes in hemoglobin levels. Among the 96 patients with C\n                      <jats:sub>min<\/jats:sub>\n                      \u226416 mg\/L, multivariate analysis identified C\n                      <jats:sub>min<\/jats:sub>\n                      as an independent risk factor for thrombocytopenia but not for anemia. Furthermore, no significant difference in thrombocytopenia risk was found between patients with C\n                      <jats:sub>min<\/jats:sub>\n                      levels of 8\u201314.5 mg\/L and those with C\n                      <jats:sub>min<\/jats:sub>\n                      of &lt;8 mg\/L (odds ratio, 1.183; 95% confidence interval, 0.428\u20133.275;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.746).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>\n                      In elderly patients, hematological side effects did not increase with increasing C\n                      <jats:sub>min<\/jats:sub>\n                      levels up to 14.5 mg\/L. These findings suggest that a target C\n                      <jats:sub>min<\/jats:sub>\n                      range of 2\u201314.5 mg\/L may be appropriate for the elderly population receiving linezolid.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial registration number:<\/jats:title>\n                    <jats:p>ChiCTR2100045707; April 23, 2021.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001364","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T17:03:34Z","timestamp":1755623014000},"page":"e104-e111","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Different Linezolid Concentration Levels on Hematologic Side Effects: A New Target for Therapeutic Drug Monitoring"],"prefix":"10.1097","volume":"47","author":[{"given":"Tingting","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China;"},{"name":"Medical School of Chinese PLA, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Adult Cardiac Surgery, Sixth Medical Center of Chinese PLA General Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangrui","family":"Geng","sequence":"additional","affiliation":[{"name":"Medical School of Chinese PLA, Beijing, China;"},{"name":"Department of Critical Care Medicine, 920th Hospital of Joint Logistics Support Force of Chinese PLA, Kunming, Yunnan Province, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zidu","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Basic Medicine, Hebei University Medical Science Center, Baoding, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junshuai","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewei","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomin","family":"Chen","sequence":"additional","affiliation":[{"name":"BGI Genomics Co, Ltd, Shenzhen, China; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangqun","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixin","family":"Xie","sequence":"additional","affiliation":[{"name":"College of Pulmonary and Critical Care Medicine, 8th Medical Center of Chinese PLA General Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxia","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, The Second Medical Center and National Clinical Research Center for Geriatric Diseases, Chinese PLA General Hospital, Beijing, China;"},{"name":"Medical School of Chinese PLA, Beijing, China;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"R1-20251107","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/FTD.0000000000000710","article-title":"Therapeutic drug monitoring can improve linezolid dosing regimens in current clinical practice: a review of linezolid pharmacokinetics and pharmacodynamics","volume":"42","author":"Rao","year":"2020","journal-title":"Ther Drug Monit."},{"key":"R2-20251107","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children [published correction appears in Clin Infect Dis. 2011;53(3):319]","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis."},{"key":"R3-20251107","doi-asserted-by":"crossref","first-page":"106329","DOI":"10.1016\/j.ijantimicag.2021.106329","article-title":"Comparison of linezolid step-down therapy to standard parenteral therapy in methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"57","author":"Yeager","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"R4-20251107","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jinf.2012.08.007","article-title":"Efficacy of linezolid-based salvage therapy compared with glycopeptide-based therapy in patients with persistent methicillin-resistant Staphylococcus aureus bacteremia","volume":"65","author":"Park","year":"2012","journal-title":"J Infect."},{"key":"R5-20251107","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3390\/antibiotics12040697","article-title":"Effectiveness and safety of linezolid versus vancomycin, teicoplanin, or daptomycin against methicillin-resistant Staphylococcus aureus bacteremia: a systematic review and meta-analysis","volume":"12","author":"Kawasuji","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"R6-20251107","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1093\/jac\/dkab036","article-title":"Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK","volume":"76","author":"Brown","year":"2021","journal-title":"J Antimicrob Chemother."},{"key":"R7-20251107","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.ijantimicag.2014.05.010","article-title":"Analysis of thrombocytopenic effects and population pharmacokinetics of linezolid: a dosage strategy according to the trough concentration target and renal function in adult patients","volume":"44","author":"Matsumoto","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"R8-20251107","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jsps.2019.09.002","article-title":"Determining therapeutic trough ranges for linezolid","volume":"27","author":"Alsultan","year":"2019","journal-title":"Saudi Pharm J."},{"key":"R9-20251107","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.drup.2018.10.002","article-title":"Update on prevalence and mechanisms of resistance to linezolid, tigecycline and daptomycin in enterococci in Europe: towards a common nomenclature","volume":"40","author":"Bender","year":"2018","journal-title":"Drug Resist Updat"},{"key":"R10-20251107","doi-asserted-by":"crossref","first-page":"493","DOI":"10.21037\/atm.2020.03.207","article-title":"Does the conventional dosage of linezolid necessitate therapeutic drug monitoring? Experience from a prospective observational study","volume":"8","author":"Fang","year":"2020","journal-title":"Ann Transl Med."},{"key":"R11-20251107","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1128\/AAC.01885-13","article-title":"Clinical population pharmacokinetics and toxicodynamics of linezolid","volume":"58","author":"Boak","year":"2014","journal-title":"Antimicrob Agents Chemother."},{"key":"R12-20251107","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1177\/0091270009337947","article-title":"Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients","volume":"49","author":"Abe","year":"2009","journal-title":"J Clin Pharmacol."},{"key":"R13-20251107","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ijantimicag.2016.08.023","article-title":"Therapeutic drug management of linezolid: a missed opportunity for Clinicians?","volume":"48","author":"Cattaneo","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"R14-20251107","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40262-020-00964-1","article-title":"Supra-therapeutic linezolid trough concentrations in elderly patients: a call for action?","volume":"60","author":"Cattaneo","year":"2021","journal-title":"Clin Pharmacokinet."},{"key":"R15-20251107","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1007\/s00228-017-2303-6","article-title":"Is it time to revise linezolid dose in elderly patients?","volume":"73","author":"Tinelli","year":"2017","journal-title":"Eur J Clin Pharmacol."},{"key":"R16-20251107","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1093\/jac\/dkae188","article-title":"Therapeutic drug monitoring of linezolid and exploring optimal regimens and a toxicity-related nomogram in elderly patients: a multicentre, prospective, non-interventional study","volume":"79","author":"Liu","year":"2024","journal-title":"J Antimicrob Chemother."},{"key":"R17-20251107","doi-asserted-by":"crossref","first-page":"117704","DOI":"10.1016\/j.cca.2023.117704","article-title":"Liquid chromatography-tandem mass spectrometry methods for quantification of total and free antibiotic concentrations in serum and exudate from patients with post-sternotomy deep sternal wound infection receiving negative pressure wound therapy","volume":"554","author":"Brozmanov\u00e1","year":"2024","journal-title":"Clin Chim Acta"},{"key":"R18-20251107","doi-asserted-by":"crossref","first-page":"116489","DOI":"10.1016\/j.jpba.2024.116489","article-title":"An LCMS\/MS method for the simultaneous determination of ten antimicrobials and its application in critically ill patients","volume":"252","author":"Liu","year":"2025","journal-title":"J Pharm Biomed Anal."},{"key":"R19-20251107","doi-asserted-by":"crossref","first-page":"e00687-17","DOI":"10.1128\/AAC.00687-17","article-title":"Systematic therapeutic drug monitoring for linezolid: variability and clinical impact","volume":"61","author":"Galar","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"R20-20251107","doi-asserted-by":"crossref","first-page":"604680","DOI":"10.3389\/fmed.2021.604680","article-title":"Incidence and associated risk factors for lactic acidosis induced by linezolid therapy in a case-control study in patients older than 85 years","volume":"8","author":"Liu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R21-20251107","doi-asserted-by":"crossref","first-page":"967311","DOI":"10.3389\/fpubh.2022.967311","article-title":"Expert consensus statement on therapeutic drug monitoring and individualization of linezolid","volume":"10","author":"Lin","year":"2022","journal-title":"Front Public Health"}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001364","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T19:00:37Z","timestamp":1762542037000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001364"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":21,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001364","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"2025-02-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-06-12","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}